Onward is the leader in the spinal cord stimulation space. They focus on targeted, programmed stimulation of the spinal cord to restore movement and other functions, alone or in combination with BCIs for thought-driven movement. Representing some of our most mature technologies, their first FDA approval is on track with the device going to market in 2024.
Invested in breaking
through paralysis
Invested in breaking through paralysis
Backed by leading global foundations
A philanthropic vehicle run with the rigor of a VC fund
Backed by the leading foundations for spinal cord injury in the US and Europe, and advised by world-class neuroscientists, we invest in early-stage companies developing cure-oriented therapies for spinal cord injury and other related markets.
What’s at stake
We invest globally in companies with the greatest potential to impact our mission, typically at the Seed and Series A stages.
Axonis Therapeutics is developing medicines for neuron restoration and neuromodulation. Therapies are aimed at enabling neural tissue to resist degeneration, restore healthy electrical balance, and promote neural regeneration. Successful pre-clinical POC studies have been completed, and a clinical trial is planned for 2024 / 25.
From the lab to the clinic, faster
We invest in the best companies, built around the most innovative and rigorous scientific advancements, with the greatest potential to impact the lives of those living with spinal cord injury.
Professionals with a personal investment
Our team combines entrepreneurial expertise, excellence in neuroscience and intensely personal dedication to curing Spinal cord injury.